Advertisement

Advertisement

CORT Stock Latest News

Corcept Resubmits FDA Application for Relacorilant in Cushing’s

Company AnnouncementsCorcept Resubmits FDA Application for Relacorilant in Cushing’s

Corcept Therapeutics resubmits NDA for Relacorilant in Cushing’s Syndrome

PremiumThe Fly

Corcept Therapeutics resubmits NDA for Relacorilant in Cushing’s Syndrome

20d ago

Mega-Cap Concentration Has Hidden Active Growth’s Best Story: Inside the F/m Emerald Special Situations ETF (SPIT) and a 1st-Percentile Morningstar Track Record

PremiumMarket News

Mega-Cap Concentration Has Hidden Active Growth’s Best Story: Inside the F/m Emerald Special Situations ETF (SPIT) and a 1st-Percentile Morningstar Track Record

26d ago

Corcept announces presentation of new data from Catalyst, Momentum trials

PremiumThe Fly

Corcept announces presentation of new data from Catalyst, Momentum trials

1M ago

Corcept Faces Amended Qui Tam Complaint After DOJ Exit

PremiumCompany Announcements

Corcept Faces Amended Qui Tam Complaint After DOJ Exit

1M ago

Corcept stockholders approve expanded incentive plan and board

PremiumCompany AnnouncementsCorcept stockholders approve expanded incentive plan and board

1M ago

Corcept Therapeutics price target raised to $135 from $110 at Canaccord

The Fly

Corcept Therapeutics price target raised to $135 from $110 at Canaccord

1M ago

Corcept Therapeutics price target raised to $95 from $75 at H.C. Wainwright

The Fly

Corcept Therapeutics price target raised to $95 from $75 at H.C. Wainwright

1M ago

Corcept Therapeutics to resubmit NDA to U.S. FDA for relacorilant

PremiumThe Fly

Corcept Therapeutics to resubmit NDA to U.S. FDA for relacorilant

1M ago

Corcept Therapeutics upgraded to Buy from Neutral at UBS

PremiumThe Fly

Corcept Therapeutics upgraded to Buy from Neutral at UBS

2M ago

Corcept Therapeutics upgraded to Buy from Neutral at UBS

PremiumThe Fly

Corcept Therapeutics upgraded to Buy from Neutral at UBS

2M ago

Corcept Therapeutics Signals Big Growth After Key Wins

PremiumCompany Announcements

Corcept Therapeutics Signals Big Growth After Key Wins

2M ago

Corcept Therapeutics price target raised to $75 from $60 at H.C. Wainwright

PremiumThe FlyCorcept Therapeutics price target raised to $75 from $60 at H.C. Wainwright

2M ago

Corcept Therapeutics price target raised to $88 from $73 at Piper Sandler

The Fly

Corcept Therapeutics price target raised to $88 from $73 at Piper Sandler

2M ago

Corcept Therapeutics announced 2-year OS data from Phase 2 dazucorilant study

The Fly

Corcept Therapeutics announced 2-year OS data from Phase 2 dazucorilant study

2M ago

Corcept Therapeutics Guides Higher on Lifyorli-Fueled Revenue Growth

PremiumCompany Announcements

Corcept Therapeutics Guides Higher on Lifyorli-Fueled Revenue Growth

2M ago

Corcept Therapeutics reports Q1 EPS (30c), consensus (14c)

PremiumThe Fly

Corcept Therapeutics reports Q1 EPS (30c), consensus (14c)

2M ago

Corcept Therapeutics raises FY26 revenue view to $950M-$1.05B, consensus $933.2M

PremiumThe Fly

Corcept Therapeutics raises FY26 revenue view to $950M-$1.05B, consensus $933.2M

2M ago

Analyst Reiterates Buy on Corcept, Sees Upside with Unchanged $110 Target as Korlym Growth Set to Re-Accelerate and Lifyorli Ramps

PremiumRatings

Analyst Reiterates Buy on Corcept, Sees Upside with Unchanged $110 Target as Korlym Growth Set to Re-Accelerate and Lifyorli Ramps

2M ago

Is CORT a Buy, Before Earnings?

PremiumPre-EarningsIs CORT a Buy, Before Earnings?

2M ago

Corcept Therapeutics presents final overall survival data from ROSELLA trial

The Fly

Corcept Therapeutics presents final overall survival data from ROSELLA trial

3M ago

Shareholders Sue Corcept Therapeutics Over Cushing’s Syndrome Drug Claims

Market News

Shareholders Sue Corcept Therapeutics Over Cushing’s Syndrome Drug Claims

3M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >